Marconi Ettore, Lombardo Francesco Paolo, Micheletto Claudio, Uberti Marzio, Di Marco Fabiano, Rossi Alessandro, Cricelli Claudio, Lapi Francesco
Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.
Italian College of General Practitioners and Primary Care, Florence, Italy.
Curr Med Res Opin. 2024 Oct;40(10):1821-1826. doi: 10.1080/03007995.2024.2399279. Epub 2024 Sep 19.
COPD management and therapy have been periodically revised to support a more patient-specific approach. Several concerns remain in primary care, such as the proper choice of initial treatment, medication adherence, and missing values for spirometry investigations. These concerns may be exacerbated by inconsistencies between the GOLD23 report and reimbursement criteria, as per the Italian NOTA99, especially for what concerns the assessment of disease severity and related treatment choice. We therefore examined the perception and knowledge of general practitioners (GPs) on COPD management and treatment.
We conducted an exploratory e-Delphi study among 600 GPs. The study examined the COPD-related GP's access to spirometry evaluations in primary care clinics; knowledge on early recognition of COPD and related clinical concerns; perception of the clinical application of the NOTA99; the place in therapy of the triple LABA/LAMA/ICS combination.
Among 466 participating GPs (response rate: 70.3%; mean age 52, SD: 14.2; mean years of experience: 21.3, SD: 15) had a good level of knowledge about the GOLD 2023 document and the reimbursement criteria for COPD medications. Nevertheless, a low (34%) direct access to spirometry was reported, along with absence of consensus on the proper choice of initial treatment (especially of use of LABA/LAMA combination), and the re-evaluation of free-triple therapy LABA/LAMA/ICS through specialist's referral.
This study captured the domains on which further training for GPs might be implemented to improve the management and treatment of COPD. An extension of this e-Delphi to a larger GPs' panel might further confirm these findings.
慢性阻塞性肺疾病(COPD)的管理和治疗方案已定期修订,以支持更具患者特异性的方法。基层医疗中仍存在一些问题,例如初始治疗的正确选择、药物依从性以及肺功能检查结果缺失等。根据意大利NOTA99,慢性阻塞性肺疾病全球倡议(GOLD)2023报告与报销标准之间的不一致可能会加剧这些问题,尤其是在疾病严重程度评估和相关治疗选择方面。因此,我们研究了全科医生(GPs)对COPD管理和治疗的认知与了解。
我们对600名全科医生进行了一项探索性电子德尔菲研究。该研究调查了全科医生在基层医疗诊所进行COPD相关肺功能评估的情况;对COPD早期识别及相关临床问题的了解;对NOTA99临床应用的认知;三联长效β2受体激动剂(LABA)/长效抗胆碱能药物(LAMA)/吸入性糖皮质激素(ICS)联合治疗在治疗中的地位。
466名参与研究的全科医生(回复率:70.3%;平均年龄52岁,标准差:14.2;平均从业年限:21.3年,标准差:15)对GOLD 2023文件和COPD药物报销标准有较好的了解。然而,据报告直接进行肺功能检查的比例较低(34%),并且在初始治疗的正确选择(特别是LABA/LAMA联合用药的使用)以及通过专科医生转诊对LABA/LAMA/ICS三联免费治疗进行重新评估方面缺乏共识。
本研究确定了可能需要对全科医生进行进一步培训以改善COPD管理和治疗的领域。将此电子德尔菲研究扩展到更大规模的全科医生群体可能会进一步证实这些发现。